PICO Portalanswers from OpenAlex & ORCID
Daniel E. Fürst
ResearcherPublications, citations & collaboration network
Daniel E. Fürst is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Daniel E. Fürst have?
PICO Portalindexed works
Daniel E. Fürst has 363 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Daniel E. Fürst have?
PICO Portalcitation count
Daniel E. Fürst has 34,727 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Daniel E. Fürst?
PICO Portalh-index
Daniel E. Fürst has an h-index of 82 in OpenAlex.
What is the i10-index of Daniel E. Fürst?
PICO Portali10-index
Daniel E. Fürst has an i10-index of 239 in OpenAlex.
What is the ORCID of Daniel E. Fürst?
PICO Portalorcid
The ORCID for Daniel E. Fürst is on the source record.
What is the OpenAlex record for Daniel E. Fürst?
PICO Portalopenalex
The OpenAlex for Daniel E. Fürst is on the source record.
What are the most-cited papers on Daniel E. Fürst?
PICO Portalmost cited works
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair, Daniel E. Fürst, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S Smolen, Michael H. Weisman, Paul Emery, Marc Feldmann, Gregory R. Harriman, Ravinder N. Maini
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
David T. Felson, Jennifer J. Anderson, Maarten Boers, Claire Bombardier, Daniel E. Fürst, Charles H. Goldsmith, Linda M. Katz, Robert W. Lightfoot, Harold E. Paulus, Vibeke Strand, Peter Tugwell, Michael E. Weinblatt, H. James Williams, Frederick Wolfe, Stephanie Kieszak
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld, Daniel E. Fürst, Joachim R. Kalden, Michael H. Weisman, Josef S. Smolen, Paul Emery, Gregory R. Harriman, Marc Feldmann, Peter E. Lipsky
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh, Joel M. Kremer, Larry W. Moreland, James R. O’Dell, Kevin Winthrop, Timothy Beukelman, S. Louis Bridges, W. Winn Chatham, Harold E. Paulus, María E. Suarez‐Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Eileen Moynihan, Karen S. Kolba, Archana Jain, Elizabeth R. Volkmann, Harsh Agrawal, Sangmee Bae, Amy S. Mudano, Nivedita M. Patkar, Kenneth G. Saag
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
Christian Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E. Fürst, Jerry A. Molitor, Edward Keystone, Dafna D. Gladman, Bernhard Manger, Siegfried Wassenberg, Ralf Weier, Daniel J. Wallace, Michael H. Weisman, Joachim R. Kalden, Josef S Smolen